MBX Biosciences, Inc.
corporate_fare Company Profile
MBX Biosciences, Inc. (NASDAQ:MBX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for MBX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for MBX spans 8-K, SCHEDULE 13D/A, 10-Q, DEFA14A.
Recent high-impact activity:
- MBX Posts $62.4M Q3 Loss; $481.6M Cash Funds Runway Into 2029
- Q3 Loss Widens to $62.4M on Former-CEO Stock Comp; $481.6M Cash Funds Runway Into 2029
- MBX Doses First Patient in Pivotal Phase 3 Trial for Once-Weekly Hypoparathyroidism Drug
- OrbiMed Unloads $33.5M in MBX Shares, Stake Falls to 6.4%
- MBX Q2 2026: $418.6M Cash, Runway Into 2029; Phase 3 Start and CEO Change
Financial Snapshot
Short Interest & Short Volume
7.90 days to coverFINRA reported short interest of 4,285,299 shares in MBX as of the October 30, 2026 settlement, a 3.1% decrease from the prior period — about 7.9 days to cover at its recent average daily volume. On November 19, 2026, 73.2% of MBX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.